More on DSNKY
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $16.92 |
|
|||
| Open | $16.92 | ||||
| 52 Wk High | $26.24 | ||||
| 52 Wk Low | $18.86 | ||||
| Day High | $16.92 | ||||
| Day Low | $16.92 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 12 | ||||
- Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) PT Lowered to JPY4,000 at Nomura/Instinet
- Goldman Sachs Reiterates Buy Rating on Daiichi Sankyo Company, Limited (4568:JP) (DSNKY)
- JPMorgan Downgrades Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) to Neutral
- Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO
- Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026
- Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Cand
- Enhertu gets EU panel backing for HER2 positive metastatic solid tumors
- Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
- Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer
- Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) PT Lowered to JPY5,500 at Macquarie
Entities mentioned with DSNKY
- FDA | View Related Stories »
- Twitter | View Related Stories »
- S1 | View Related Stories »
- Deutsche Bank | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
